miREIA – miRNA enzyme immunoassay
Whole blood, PBMC
Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).
12.5 – 0.39 amol/μl
Limit of Detection
n = 8,
CV = 8.7%
n = 5,
CV = 10.3%
- It is intended for research use only
- The total assay time is less than 2.5 hours
- The kit measures hsa-miR-15a-5p isolated from human blood
- Assay format is 96 wells
- Standard is synthetic miRNA-based
- Components of the kit are provided ready to use, concentrated or dried
Cardiovascular disease, Diabetology - Other Relevant Products, Oncology
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
The gene for miR-15a is located on the chromozome 13q14.
Functional studies have reported that miR-15a positively regulates pancreatic β-cell function and insulin synthesis and negatively affects adipogenesis. It was also shown that miR-15a is increased in plasma of diabetic patients, correlating with disease severity.
miR-15a is downregulated in many types of cancer, including prostate cancer, colorectal cancer, hepatoma, prostate cancer, chronic lymphocytic leukemia, nasopharyngeal carcinoma, malignant melanoma, human brain glioma and breast cancer. It acts as a tumor suppressor, promoting apoptosis and inhibiting cell proliferation by targeting multiple oncogenes, including Bcl-2, Mcl1, CcnD1 and Wnt3A.
Besides cancer, circulating miR-15a is downregulated in patients with ST-segment elevated myocardial infarction, compared to healthy controls.